青光眼：当前及新的治疗方法
Glaucoma: Current and New Therapeutic Approaches.
作者信息
Lee Hsin-Pei, Tsung Ta-Hsin, Tsai Yu-Chien, Chen Yi-Hao, Lu Da-Wen
机构信息
Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.
Department of Ophthalmology, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan.
出版信息
Biomedicines. 2024 Sep 3;12(9):2000. doi: 10.3390/biomedicines12092000.
Abstract
Glaucoma is identified by the loss of retinal ganglion cells (RGCs). The primary approach to managing glaucoma is to control intraocular pressure (IOP). Lately, there has been an increasing focus on neuroprotective therapies for glaucoma because of the limited effectiveness of standard methods in reducing IOP and preventing ongoing vision deterioration in certain glaucoma patients. Various drug-based techniques with neuroprotective properties have demonstrated the ability to decrease the mortality of retinal ganglion cells. This study will analyze the currently recommended drug-based techniques for neuroprotection in the prospective treatment of glaucoma.
摘要
青光眼是由视网膜神经节细胞（RGCs）的丧失所确定的。治疗青光眼的主要方法是控制眼压（IOP）。最近，由于标准方法在降低眼压和预防某些青光眼患者持续视力恶化方面效果有限，对青光眼神经保护疗法的关注日益增加。各种具有神经保护特性的基于药物的技术已证明有能力降低视网膜神经节细胞的死亡率。本研究将分析目前推荐的用于青光眼前瞻性治疗的基于药物的神经保护技术。
相似文献
1
Glaucoma: Current and New Therapeutic Approaches.青光眼：当前及新的治疗方法
Biomedicines. 2024 Sep 3;12(9):2000. doi: 10.3390/biomedicines12092000.
2
Upregulation of the endothelin A (ET) receptor and its association with neurodegeneration in a rodent model of glaucoma.内皮素A（ET）受体上调及其与青光眼啮齿动物模型中神经退行性变的关联。
BMC Neurosci. 2017 Mar 1;18(1):27. doi: 10.1186/s12868-017-0346-3.
3
Neuroprotective Strategies in Glaucoma.青光眼的神经保护策略
Curr Pharm Des. 2016;22(14):2178-92. doi: 10.2174/1381612822666160128144747.
4
Glaucomatous optic neuropathy: Mitochondrial dynamics, dysfunction and protection in retinal ganglion cells.青光眼性视神经病变：视网膜神经节细胞中的线粒体动力学、功能障碍及保护
Prog Retin Eye Res. 2023 Jul;95:101136. doi: 10.1016/j.preteyeres.2022.101136. Epub 2022 Nov 16.
5
Risk Factors for Retinal Ganglion Cell Distress in Glaucoma and Neuroprotective Potential Intervention.青光眼视网膜神经节细胞损伤的风险因素和神经保护的潜在干预作用。
Int J Mol Sci. 2021 Jul 27;22(15):7994. doi: 10.3390/ijms22157994.
6
Regulated Cell Death of Retinal Ganglion Cells in Glaucoma: Molecular Insights and Therapeutic Potentials.青光眼致视网膜神经节细胞程序性死亡的研究进展
Cell Mol Neurobiol. 2023 Oct;43(7):3161-3178. doi: 10.1007/s10571-023-01373-1. Epub 2023 Jun 20.
7
A review of potential novel glaucoma therapeutic options independent of intraocular pressure.一篇关于独立于眼内压的潜在新型青光眼治疗选择的综述。
Surv Ophthalmol. 2022 Jul-Aug;67(4):1062-1080. doi: 10.1016/j.survophthal.2021.12.003. Epub 2021 Dec 8.
8
A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma.一种 Fas 受体的小肽拮抗剂可抑制神经炎症，防止诱导型青光眼小鼠模型中的轴突变性和视网膜神经节细胞死亡。
J Neuroinflammation. 2019 Sep 30;16(1):184. doi: 10.1186/s12974-019-1576-3.
9
Neuroprotection in glaucoma: recent advances and clinical translation.青光眼的神经保护：最新进展及临床转化。
Clin Exp Ophthalmol. 2019 Jan;47(1):88-105. doi: 10.1111/ceo.13336. Epub 2018 Jul 1.
10
Rational Basis for Nutraceuticals in the Treatment of Glaucoma.营养保健品治疗青光眼的合理基础。
Curr Neuropharmacol. 2018;16(7):1004-1017. doi: 10.2174/1570159X15666171109124520.
引用本文的文献
1
Nd:YAG laser peripheral iridotomy for reverse pupillary block: a case report.钕钇铝石榴石激光周边虹膜切开术治疗逆瞳孔阻滞：病例报告
Int J Ophthalmol. 2025 Aug 18;18(8):1606-1609. doi: 10.18240/ijo.2025.08.25. eCollection 2025.
2
A Personal Scientific Journey in Ophthalmology: Twenty-Five Years of Translating Research into Novel Therapies.眼科领域的个人科学之旅：将研究转化为新型疗法的二十五年
Pharmaceuticals (Basel). 2025 Jun 12;18(6):883. doi: 10.3390/ph18060883.
3
Gonioscopy-Assisted Transluminal Trabeculotomy versus Bent Ab Interno Needle Goniectomy in Patients with Open-Angle Glaucoma.开角型青光眼患者行房角镜辅助经腔小梁切开术与内路弯针巩膜切开术的比较
Turk J Ophthalmol. 2025 Jun 25;55(3):141-147. doi: 10.4274/tjo.galenos.2025.44773.
本文引用的文献
1
Optic Nerve Neuroprotection in Glaucoma: A Narrative Review.青光眼的视神经神经保护：一篇叙述性综述
J Clin Med. 2024 Apr 11;13(8):2214. doi: 10.3390/jcm13082214.
2
Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial.曲伏前列素前房内植入治疗开角型青光眼或高眼压症：一项随机双盲试验的12个月结果
Ophthalmol Ther. 2024 Apr;13(4):995-1014. doi: 10.1007/s40123-024-00898-y. Epub 2024 Feb 12.
3
Real-World Study of the Effectiveness and Safety of Intracameral Bimatoprost Implant in a Clinical Setting in the United States.美国临床环境中前房注射比马前列素植入物有效性和安全性的真实世界研究。
Clin Ophthalmol. 2024 Jan 19;18:187-199. doi: 10.2147/OPTH.S445005. eCollection 2024.
4
Overview of Recent Advances in Nano-Based Ocular Drug Delivery.基于纳米的眼部药物输送的最新进展概述。
Int J Mol Sci. 2023 Oct 19;24(20):15352. doi: 10.3390/ijms242015352.
5
Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy.Rho激酶抑制剂作为青光眼治疗的新兴靶点。
Ophthalmol Ther. 2023 Dec;12(6):2943-2957. doi: 10.1007/s40123-023-00820-y. Epub 2023 Oct 14.
6
Efficacy of citicoline as a supplement in glaucoma patients: A systematic review.胞磷胆碱作为青光眼患者补充剂的疗效：系统评价。
PLoS One. 2023 Sep 28;18(9):e0291836. doi: 10.1371/journal.pone.0291836. eCollection 2023.
7
Nanotechnology-based ocular drug delivery systems: recent advances and future prospects.基于纳米技术的眼部药物传递系统：最新进展与未来展望。
J Nanobiotechnology. 2023 Jul 22;21(1):232. doi: 10.1186/s12951-023-01992-2.
8
Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering.青光眼的神经保护：眼压降低以外的机制。
Mol Aspects Med. 2023 Aug;92:101193. doi: 10.1016/j.mam.2023.101193. Epub 2023 Jun 16.
9
Neuroprotective effect of the calcium channel blocker nilvadipine on retinal ganglion cell death in a mouse ocular hypertension model.钙通道阻滞剂尼伐地平对小鼠高眼压模型视网膜神经节细胞死亡的神经保护作用。
Heliyon. 2023 Feb 16;9(3):e13812. doi: 10.1016/j.heliyon.2023.e13812. eCollection 2023 Mar.
10
Erythropoietin in Glaucoma: From Mechanism to Therapy.红细胞生成素在青光眼：从机制到治疗。
Int J Mol Sci. 2023 Feb 3;24(3):2985. doi: 10.3390/ijms24032985.
Zotero 插件